Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review


Eksin M. A. , ERDEN A. , Güven S. C. , Armagan B., Ozdemir B., Karakas O., ...More

Immunotherapy, vol.14, no.6, pp.401-408, 2022 (Refereed Journals of Other Institutions) identifier identifier

  • Publication Type: Article / Article
  • Volume: 14 Issue: 6
  • Publication Date: 2022
  • Doi Number: 10.2217/imt-2021-0128
  • Title of Journal : Immunotherapy
  • Page Numbers: pp.401-408
  • Keywords: ankylosing spondylitis, multiple sclerosis, psoriatic arthritis, secukinumab

Abstract

Background/aim: Multiple sclerosis (MS) is a demyelinating central nervous system disorder with few cases reported to have concomitant spondyloarthritis (SpA) spectrum disorders such as ankylosing spondylitis and psoriatic arthritis. The aim of this study is to evaluate the effectiveness of secukinumab in the treatment of MS and accompanying ankylosing spondylitis or psoriatic arthritis. Materials & methods: In addition to four cases of their own, the authors conducted a systematic literature search. Demographics, comorbidities, symptoms of MS and SpA, medical treatments and changes in clinical and laboratory findings with treatment were recorded. Results & conclusions: After secukinumab therapy, all patients were found to have treatment response regarding axial involvement, without any progression of MS observed. For both SpA spectrum diseases and MS, secukinumab may be an appropriate choice. Background/aim: Multiple sclerosis (MS) is a central nervous system disorder, with rare cases reported to have associated spondyloarthritis (SpA) spectrum disorders such as rheumatic disease of the backbone and psoriasis-related rheumatic disease. The aim of this study is to evaluate the effectiveness of the drug secukinumab in the treatment of MS and accompanying rheumatic disease of the backbone and psoriasis-related rheumatic disease. Materials & methods: In addition to four cases of their own, the authors conducted a systematic literature search. Demographics, the presence of other diseases, symptoms of MS and SpA, medical treatments and changes in clinical and laboratory findings with treatment were recorded. Results & conclusions: After secukinumab therapy, all patients were found to have treatment response, without any progression of MS observed. For both SpA spectrum diseases and MS, secukinumab may be an appropriate choice.